Insmed’s Amikacin Gains US FDA Panel Nod For Refractory Lung Disease

But advisory committee recommends against sponsor's broader indication that would include first-line use in adults with nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex; panel narrowly endorses surrogate endpoint of sputum culture conversion.

FDA Advisory Committee Feature image

The US FDA’s Antimicrobial Drugs Advisory Committee on Aug. 7 strongly supported approval of Insmed Inc.’s amikacin liposome inhalation suspension (ALIS) in nontubercuolous mycobacterial (NTM) lung disease but for a narrower indication than that sought by the company.

The panel voted 12-2 that the efficacy and safety data support use in adults with NTM caused by Mycobacterium avium...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers